SCHEMBL5865511

SCHEMBL5865511

CS(=O)(=O)c1cc(C(=C(Cl)Cl)c2ccc(Cl)cc2)ccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.53
MAPK1 P28482 2/20 0.53
TSHR P16473 2/20 0.53
CYP3A4 P08684 1/20 0.53
ATM Q13315 1/20 0.53
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.40
MAOB P27338 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CA1 P00915 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865564 0.88 MAPT (0.43) L3MBTL1MAPK1TSHRCYP3A4ATM
SCHEMBL5865629 0.88 MAPK1 (0.53) L3MBTL1MAPK1TSHRCYP3A4ATM
SCHEMBL5865252 0.86 SMN1; SMN2 (0.40) L3MBTL1MAPK1TSHRKMT2ASMN1; SMN2
SCHEMBL5865494 0.85 TSHR (0.50) L3MBTL1MAPK1TSHRCYP3A4ATM
SCHEMBL5865539 0.82 MAPK1 (0.50) L3MBTL1MAPK1TSHRCYP3A4ATM
SCHEMBL6575803 0.82 TSHR (0.35) L3MBTL1MAPK1TSHRCYP3A4ATM
SCHEMBL1495711 0.78 SMN1; SMN2 (0.46) L3MBTL1TSHRKMT2ASMN1; SMN2MEN1
SCHEMBL19157375 0.78 SMN1; SMN2 (0.46) L3MBTL1TSHRKMT2ASMN1; SMN2MEN1
SCHEMBL1495405 0.78 KMT2A (0.62) L3MBTL1MAPK1TSHRKMT2ASMN1; SMN2
SCHEMBL5865619 0.76 CCR2 (0.41) L3MBTL1MAPK1TSHRCYP3A4ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091248-B2 Treatment of adrenocortical hypersecretion and tumor growth BRANDT INGVAR 2006-08-15 US claimed
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth BRANDT INGVAR (SE) 2004-12-02 US claimed
EP-1412311-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH Brandt, Ingvar (SE) 2004-04-28 EP claimed
WO-2003002495-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH BRANDT INGVAR (SE) 2003-01-09 WO claimed
US-7091248-B2 Treatment of adrenocortical hypersecretion and tumor growth BRANDT INGVAR 2006-08-15 US disclosed
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth BRANDT INGVAR (SE) 2004-12-02 US disclosed
EP-1412311-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH Brandt, Ingvar (SE) 2004-04-28 EP disclosed
WO-2003002495-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH BRANDT INGVAR (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth NR3C2, NR5A1, NR3C1 L3MBTL1 3761/4885MAPK1 2454/4885TSHR 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.